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Pulmonary hypertension is a relevant interceding morbidity in patients with pulmonary fibrosis
that has significant impact on exercise tolerance and outcome. The aim of this study was to
further characterize the exercise intolerance, dyspnoea and ventilatory inefficiency of
patients with pulmonary fibrosis in the presence or absence of pulmonary hypertension via
cardiopulmonary exercise testing.
Thirty-four patients underwent pulmonary function testing, symptom-limited exercise
testing on a bicycle and dyspnoea evaluation according to the BORG scale. Pulmonary
hypertension was assessed by echocardiography and in a subset of patient’s right heart
catheterization.
Sixteen of 34 patients with pulmonary fibrosis revealed pulmonary hypertension. While all
study patients did not differ in lung functions and demographic characteristics, patients
suffering from pulmonary hypertension showed a significantly impaired exercise tolerance
and worsened ventilatory inefficiency. The extent of pulmonary artery pressure elevation
impacted significantly on ventilatory inefficiency. In addition, the increased ventilatory
requirements significantly influenced the extent of dyspnoea in patients with pulmonary
hypertension.34 8622401; fax: þ49 3834 8622422.
il.com (S. Gla¨ser).
8 Elsevier Ltd. All rights reserved.
318 S. Gla¨ser et al.We conclude that pulmonary hypertension has a significant impact on exercise capacity and
dyspnoea in patients with interstitial lung disease (ILD). The further impairment of exercise
capacity as well as the extent of dyspnoea in patients with interceding PHT is attributable
to a significantly impaired ventilatory inefficiency.
ª 2008 Elsevier Ltd. All rights reserved.Background
Cardiopulmonary exercise testing (CPET) has become
increasingly important in patients with several cardiac and
pulmonary diseases. It has been applied to patients with
chronic congestive heart failure (CHF) and pulmonary
hypertension (PHT) for risk stratification1,2 and to assess
responses to therapeutic interventions.3,4 In addition to
its ability to evaluate exercise tolerance ventilatory
inefficiency, which is usually expressed as the relationship
between minute ventilation and carbon dioxide output (VE
vs. VCO2 slope), CPET has become increasingly important
due to its prognostic and therapeutic implications5,6 in
patients with cardiac limitations. In CHF patients, increased
ventilatory requirements, and thus ventilatory inefficiency,
are predominately attributable to increased dead space
fraction ventilation and hyperventilation independent of
lactic acidosis.7 Ventilatory inefficiency has been shown to
be the most relevant correlate of dyspnoea.8,9
PHT is a common and prognostically important disorder
affecting w45% of patients with advanced interstitial lung
disease (ILD).10 In recent years, there has been a growing
appreciation for the role of an interceding PHT in the
clinical course of different types of ILD. The influence of
PHT on exercise tolerance and survival of patients with ILD
has been demonstrated by several investigators.10e13 An
interceding PHT results in a significantly impaired 6-min
walking distance (6-MWT).11 In addition, the influence of
PHT on resting lung function (PFT) in these patients has
been described.14 Nadrous et al. showed a significant
influence of the extent of PHT on diffusing capacity of
carbon monoxide and subsequently on survival.15
However, little is known about the mechanisms of
exercise limitation and dyspnoea in patients suffering from
PHT and ILD. Patients with advanced ILD are generally
thought to be limited by the abnormalities in lung function.
On the other hand, an increased ventilatory response to
exercise appears to be a uniform finding in the majority of
PHT patients. Dyspnoea in this patient population can be
attributed to at least 3 relevant mechanisms that increase
ventilatory drive relative to metabolism.16 The first is
ventilation/perfusion mismatching which results in an
increased ratio of dead space volume to tidal volume due to
hypoperfusion of ventilated alveoli.17 The second mecha-
nism is the increased hydrogen ion stimulus to ventilation
resulting from low work rate lactic acidosis, and therefore an
adequate hyperventilation to maintain acidebase balance.
The third mechanism is due either to a reduced pulmonary
capillary bed with shortened red blood cell transit times, or
to a right-to-left shunt through a patent foramen ovale.
The objective of the present study was to determine the
exercise capacity, gas exchange and ventilatory ineffi-
ciency in ILD patients with or without PHT by CPET, and torelate them to traditional measurements such as resting
hemodynamics and the BORG dyspnoea scale.
Methods
Study subjects
Twelve female and 22 male (mean age 57 13 yrs) subjects
volunteered to be included in the investigation. All patients
were suffering from idiopathic pulmonary fibrosis (IPF).
Diagnosis was based on the ATS criteria.18 In addition to
non-invasive ATS criteria in 16/34 patients the diagnosis of
IPF was proven by surgical lung biopsy (12 patients with, 4
without evidence of PHT). In 9/34 patients representative
tissue was sampled by transbronchial biopsy (all without
evidence of PHT). All patients had to be on chronic medi-
cation and to be clinically stable for at least 4 weeks prior
to inclusion into the study.
Patients had to be able to perform cycle ergometry.
Patients showing signs of left heart failure or primary
valvular heart disease, peripheral arterial disease, under-
lying muscular disease, relevant orthopaedic limitations or
significant anaemia were excluded from the evaluation.
Patients underwent the assessment within a regular
ambulatory evaluation for possible lung transplantation in
a University hospital. All subjects gave written informed
consent. The protocol for data acquisition and analysis was
approved by the local Ethics Committee of University of
Greifswald.
Dyspnoea assessment
The extent of dyspnoea was evaluated by self-assessment
according to the BORG CR-10 scale19 and graduated from
0 (no dyspnoea) to 10 (maximal imaginable dyspnoea).
Lung function testing
Immediately prior to CPET, each subject underwent a PFT
test which included spirometry and diffusing capacity
evaluation for carbon monoxide (TLCO and KCO as cor-
rected for alveolar surface area).
Exercise testing
Each subject performed symptom-limited CPET on a bicycle
according to a ramp test with an exercise increment of
5 W/min.
Each protocol was preceded by a resting period of at
least 3 min to enable the patients to achieve steady state
conditions for heart rate, blood pressure and gas exchange
variables, and an unloaded cycling period of 2 min.
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complex arrhythmias or critical blood pressure changes, all
tests were performed symptom-limited (volitional exertion,
dyspnoea or fatigue). Prior to CPET, all patients were
encouraged to reach maximal exhaustion.
All tests were performed according to current guidelines
for CPET20,21 with continuous monitoring of gas exchange,
12-lead ECG, blood pressure and oxygen saturation.
Gas exchange variables
Respiratory gas exchange variables were measured contin-
uously throughout the resting period, the unloaded cycling
period and the exercise test using a VIASYS Healthcare
system (Oxycon Pro, Rudolph’s mask). Prior to each test,
the equipment was calibrated with reference to the stan-
dard gas and volume calibration. Values for minute venti-
lation (VE), tidal volume (Vt), oxygen uptake (VO2), and
carbon dioxide output (VCO2) as well as end-tidal partial
pressures for oxygen (petO2) and carbon dioxide (petCO2),
were acquired on a breath-by-breath basis and averaged
over 10 s intervals. Peak oxygen uptake (peakVO2) was
defined as the highest 10-s average of VO2 in the last minute
of the exercise test. PeakVO2 in relation to the corre-
sponding heart rate was used to calculate oxygen (O2)
pulse. Ventilatory efficiency, expressed as the relation of
VE and VCO2, was defined as the slope of the regression of
both parameters excluding excess hyperventilation at the
end of exercise.1,5,8 The anaerobic threshold (AT) was
determined according to Wasserman et al.22 The breathing
reserve (VE/MVV) was calculated as maximal VE in relation
to maximal voluntary ventilation (MVV). MVV was calcu-
lated by FEV1 41.
During the exercise test, dynamic flow-volume loops
were documented at early, middle and maximal exercise.
Each manoeuvre was completed by maximal deep inspira-
tion for accurate placing of the record to the resting
spirometry and was evaluated for inspiratory capacity
(IC) to detect dynamic hyperinflation23 (DIC was calculated
as resting IC e peak exercise IC). The final manoeuvre
was assessed for peak Vt in relation to peak exercise IC
(Vt/IC).
Blood gas samples were obtained at rest and during
exercise (as closed as possible to AT) at the hyperaemic ear
lobe. The difference of end-tidal gas concentration and
capillary partial pressure was calculated for CO2 (pa-etCO2)
at AT.
Echocardiography
Each subject underwent transthoracic echocardiography by
an experienced investigator shortly before CPET (inter-
val 48 h). In addition to the right ventricular evaluation,
the echocardiography performed also focused on the left
ventricular and atrial diameters, ejection fraction and
valvular function to exclude underlying valvular diseases,
diastolic dysfunction or CHF.
Volunteers were classified as patients with or without
pulmonary arterial hypertension by echocardiography.
The following criteria were used to detect PHT and right
ventricular dysfunction:e right ventricular dilation (mid ventricular end-diastolic
diameter >35 mm and a relation of right ventricle to
left ventricle >60%) and enlargement of the right
atrium.
e tricuspid valve regurgitation velocity >2.8 m/s24 in
association with an enlarged diameter and reduced
respiratory variation of the inferior vena cava.25 Using
the Bernoulli equation (dPZ 4 v2) and assuming
a central venous pressure of 5 mmHg,24 the systolic
pulmonary arterial pressure (sPAP)was calculated. Amild
PHTwas defined by a sPAP of <50 mmHg and severe PHT
by a sPAP of >50 mmHg.
e A right ventricular myocardial performance (Tei-) index
of >0.526 and a Tricuspid Annular Plane Systolic
Excursion (TAPSE) of <15 mm27 were used to identify
the patients with impaired right ventricular function
where applicable.Right heart catheterization
For a subgroup of patients with echocardiographic evidence
of PHT, hemodynamic results of right heart catheterization
were obtained. All measurements were done at rest in
a reclining position by Swan-Ganz catheterization. PAP was
calculated as mean, diastolic and systolic pressure,
whereas pulmonary capillary wedge pressure was measured
as the mean. Cardiac output was calculated using the Fick
equation.
Statistical analysis
Comparisons between the patient groups were made using
the ManneWhitney U test. The associations were tested by
Spearman’s rank correlation. To analyse correlations
between categorical variables (BORG scale), the multiserial
correlation coefficient was used.28 P-values (2-tailed)
below 0.05 were considered statistically significant.Results
Patients’ characteristics
According to the echocardiographic and hemodynamic
criteria, 16/34 participants were classified as patients with
PHT. Their characteristics are listed in Table 1. For 9/16
patients with evidence of PHT, echocardiographic results
were substantiated by invasive hemodynamic measurement
(Table 2). The mean interval between echocardiographic
and right heart catheterization was 38 days (range 156 to
200). The correlation between sPAP assessed by echocar-
diography and right heart catheterization was 0.90
(p< 0.05).
Except for diffusing capacity, PFT showed no significant
differences between both groups. Diffusing capacity cor-
rected for ventilated area (KCO) was significantly lower in
the PHT group.
Nine patients in the PHT group showed echocardio-
graphic evidence of severe PHT (sPAP > 50 mmHg).
Patients with severe PHT had a significantly lower
Table 1 Demographic characteristics and PFT of patients
with and without PHT.
Characteristics ILD, no PHT ILD, PHT
Patients [n] 18 16
Female/male [n] 8/10 4/12
Age [years] 55.5 (31e67) 62.5 (32e81)
Raw [kPa*s/l] 0.3 (0.16e0.59) 0.25 (0.1e0.48)
VC/FVC [l] 2.4 (1.4e4.4) 2.7 (1.1e5.4)
FEV1 [l] 1.7 (1.2e3.3) 1.8 (0.9e3)
ITGV [l] 2.7 (1.5e4.5) 3.2 (1.1e6.4)
TLC [l] 4.6 (3.1e6.7) 4.9 (2.2e8.5)
KCO [mmol/min/kPa/l] 1.1 (0.6e1.5) 0.6 (0.2e1.3)**
LVEF [%] 60 (50e60) 60 (25e65)
sPAP [mmHg] 30 (21e32) 54 (32e90)**
LVEDD [mm] 45 (33e55) 44.5 (31e63)
Results are shown as the median and range or number.
**p< 0.01
Raw: airway resistance; VC: vital capacity; FVC: forced vital
capacity; FEV1: forced expiratory volume in 1 s; ITGV: intra-
thoracic gas volume; TLC: total lung capacity; KCO: diffusing
capacity for carbon dioxide corrected for alveolar surface area;
LVEF: left ventricular ejection fraction; sPAP: systolic pulmo-
nary artery pressure; and LVEDD: left ventricular end-diastolic
diameter.
320 S. Gla¨ser et al.diffusing capacity (KCO 0.37 vs. 0.75 mmol/min/kPa/l;
p< 0.05), whereas differences in lung volumes, age and
other demographic characteristics did not reach statistical
significance.
Exercise capacity and ventilatory efficiency
All patients completed the symptom-limited exercise test
without complications or premature termination. Exercise
capacity, as demonstrated by peakVO2 and VO2AT, was
significantly lower in patients with PHT (Fig. 1). Patients
with severe PHT showed a significantly impaired peakVO2
compared to patients with mild PHT (mean peakVO2 18.4
vs. 10.1 ml/kg/min; p< 0.05). Patients with PHT were
significantly more hypoxic both at rest and during exercise
(Table 3).
Ventilatory inefficiency, expressed as the VE vs. VCO2
slope, was significantly pronounced in patients with PHTTable 2 Comparison of hemodynamic data assessed by right hear
Patient number Right heart catheterization
mPAP [mmHg] sPAP [mmHg] PCWP [mm
1 40 65 8
8 29 50 2
10 31 59 3
16 31 41 4
20 29 40 6
28 31 66 4
31 27 35 4
32 38 70 6
34 30 49 7
Time delay is shown as the interval between right heart catheterizat(Fig. 2). The mean VE vs. VCO2 slope was 38 for patients
with mild PHT vs. 50 for patients with severe PHT
(p< 0.05). Overall, the sPAP of patients with PHT had
a significant impact on the VE vs. VCO2 slope (Fig. 3) and
peakVO2 (RsZ0.52; p< 0.05) but had no effect on these
parameters in non-PHT patients.
The impairment in ventilatory efficiency was accompa-
nied by significantly increased pa-etCO2 differences at
anaerobic threshold in patients with PHT (4.0 vs.
10.3 mmHg, p< 0.05).
Dyspnoea evaluation
Dyspnoea evaluation by the BORG CR-10 scale revealed
a mean score of 3 for patients without PHT and 6 in patients
with PHT (p< 0.05). Significant differences in the BORG
scale were obtained by comparing patients with mild PHT
to those with severe PHT [4 (3e7) vs. 7 (4e9); p< 0.05].
The extent of dyspnoea expressed by the BORG scale
was inversely correlated to peakVO2 (RsZ0.83:
p< 0.001) as well as to ventilatory efficiency (Fig. 4) in PHT
patients, whereas both correlations were not verifiable in
ILD patients without PHT.
Discussion
The present study showed the relevant impact of inter-
ceding PHT in patients with ILD which resulted in a consid-
erably reduced exercise capacity and worsened dyspnoea
compared to those with comparable ILD conditions but
without PHT. Furthermore, to our knowledge, this is the
first study that shows increased ventilatory requirements
and thus remarkably impaired ventilatory inefficiency in
patients with PHT and ILD as pathophysiological correlates
for amplified dyspnoea and exercise limitation.
Numerous studies have shown a relevant influence of
interceding PHT on exercise tolerance of patients with ILD.
In addition, exercise capacity, predominantly character-
ized by 6-MWT, as well as desaturation indices (SpO2 nadir)
have been shown to be more accurate predictors of survival
than PFT.12,13 In a large analysis using the United Network
for Organ Sharing (UNOS) database of patients with ILD
listed for lung transplantation, a cut-off of 207 m had the
best discriminatory power in determining survival.29 Int catheterization and echocardiography in 9 patients with PHT.
Time delay [d] Echocardiography
Hg] CI [l/min/m2] sPAP [mmHg]
1.9 156 75
2.1 49 56
1.6 200 66
2.9 166 45
3 38 n.a.
2 66 75
2.8 15 33
2.2 6 90
2.5 18 53
ion and echocardiography in days. N.a.: not applicable.
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Figure 1 Oxygen uptake during peak exercise and at anaerobic threshold (AT) [ml/kg/min] for patients with or without PHT.
**p< 0.01 between both groups.
Impact of pulmonary hypertension on gas exchange 321a recent study, a composite of 6-MWT parameters was
shown to have better performance characteristics in pre-
dicting survival.30
Nonetheless, the intriguing question raised by these
studies relates to what important prognostic factor is
captured by exercise studies that is not assessed by resting
standard PFT. Moreover, exercise-limiting factors in this
patient population remain unclear.
Corresponding to the 6-MWT performance reported by
others, our data revealed a peakVO2 of patients with PHT
that is more than one third lower than that of non-PHT
patients with ILD despite comparable resting lung volumes
and demographic characteristics. Furthermore, patients
with severe PHT (sPAP> 50 mmHg) had a significantly
reduced exercise capacity compared to those with
moderate PHT. Patients with advanced ILD are generally
thought to be limited by their impaired lung volumes as
well as hypoxemia e a pathophysiologic understanding that
has to be challenged by our results. Except for diffusing
capacity, the resting PFT did not differ between both
groups. Even under peak exercise parameters of a ventila-
tory limitation such as breathing reserve20,22 and tidal
volume to inspiratory capacity ratio,31 a comparable extent
of limitation was observed in patients with or without PHT.Table 3 Exercise characteristics of patients with and without P
Characteristics Fibrosis,
paO2 at rest [mmHg] 75 (4
paO2 on exercise [mmHg] 66 (4
PaCO2 at rest [mmHg] 40 (3
PaCO2 on exercise [mmHg] 39 (3
Max. HR [1/min] 131 (9
O2 pulse [l] 9.6 (5
Vt max [l] 1.2 (0
VE max [l] 45 (2
BF max [1/min] 38 (2
VE/MVV max [%] 63 (3
DIC [l] 0.06 (
Vt/IC max 0.83 (0
Results are given as the median and range. *p< 0.05.
paO2/CO2: arterial partial pressure for oxygen or carbon dioxide; HR: h
frequency; VE/MVV: breathing reserve; DIC was calculated as resting
capacity ratio; and max: peak exercise values.Moreover, not all patients appeared to be limited by their
lung volumes under exercise; Vt/IC as well as VE/MVV
revealed preserved volumes even at the end of exercise.
The dynamic flow-volume loops showed a relevant dynamic
hyperinflation in just a minority of the patients, never
reaching an exercise-limiting importance. Therefore we
conclude that the ventilatory volume limitation was not the
primary cause of exercise limitation in the majority of
patients and did not differentiate between PHT and non-
PHT patients.
Ventilatory inefficiency, expressed as the relation of
ventilation to carbon dioxide output, had the most relevant
impact on exercise capacity in patients with PHT and ILD.
The relevance of ventilatory inefficiency for prognosis and
dyspnoea has been shown for patients with CHF and several
groups of PHT patients by numerous investigators.1,2,4e6
Our data show that the degree of ventilatory inefficiency
strongly predicts exercise capacity among patients with
PHT. In addition, the degree of ventilatory inefficiency was
significantly correlated to the severity of PHT. Ventilatory
inefficiency reflects increased ventilatory requirements to
exhale CO2. Although hemodynamics were not invasively
monitored during exercise, we hypothesize that
a decreased cardiac output secondary to increased rightHT.
no PHT Fibrosis PHT
4e95) 59 (47e79)*
3e90) 48 (36e69)*
4e45) 40 (25e48)
2e48) 38 (25e44)
2e167) 116 (70e151)*
.2e15) 7.45 (5.2e12)
.8e2) 1.3 (0.5e2.8)
8e83) 45 (22e90)
7e54) 40 (17e60)
5e100) 69 (42e96)
0.7 to 0.7) 0.21 (0.6 to 0.2)
.6e0.96) 0.8 (0.49e1)
eart rate; Vt: tidal volume; VE: minute ventilation; BF: breathing
IC e peak IC on exercise; and Vt/IC: tidal volume to inspiratory
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322 S. Gla¨ser et al.ventricular afterload accounts for the observed effects on
exercise capacity. Hyperventilation with decreased PaCO2,
as is usually observed in patients with other forms of PHT32
and CHF,33 was not seen in the majority of our patients. In
the absence of an intracardiac right-to-left shunt, hyper-
ventilation mainly accounts for the increased VE vs. VCO2
slope observed in patients with PHT since no major abnor-
malities in pulmonary ventilation/perfusion matching have
been reported.34,35 The reasons for this phenomenon
remain unclear. Perhaps this is attributable to a reduced
pulmonary capillary bed with shortened red blood cell
transit times and thus impaired oxygenation.16 Another
mechanism that might explain increased ventilatory
requirements is an increase in functional intrapulmonary
right-to-left shunt. The decreased peak oxygen pulse,
increased pa-etCO2 difference on exercise as well as the
significantly pronounced hypoxia in PHT patients might
substantiate this theory.
Finally, ventilation perfusion mismatching can result
from a locally different vascular tone or decreased alveolar
ventilation.36 Both systemic and local hypoxia appear to
play a role in understanding the pathophysiology of ILD
patients with PHT. However, most of the studies that have
documented the presence and severity of PHT in IPF have
only taken into account normoxic conditions, implicating0 10 20 30 40 50 60 70 80 90 100
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Figure 3 Ventilatory efficiency in correlation to sPAP
[mmHg] for patients with or without PHT. ***p< 0.001.multiple causal mechanisms besides hypoxia. Numerous
mediators have been outlined as potential participants in
the pathogenesis of PHT in experimental and/or idiopathic
ILD such as 5-lipoxygenase,37 leukotriens, tumor necrosis
factor alpha, platelet-derived growth factor and prosta-
glandins.37 As shown in idiopathic pulmonary hypertension,
endothelin-1 is also a relevant molecule in the pathogenesis
of PHT in ILD.38
Although the exact mechanism remains unclear, venti-
latory inefficiency enhances the respiratory burden during
exercise and subsequently dyspnoea in patients with
different cardiac diseases as well as in ILD patients with PHT.
Our study has its limitations. First, the grading of PHT
was based on echocardiographic criteria, which may over-
estimate or underestimate pulmonary artery pressure in
this patient population.39 However, a relevant number of
patients underwent right heart catheterization once during
their clinical evaluation. The strong correlation between
echocardiographic and invasive hemodynamic results
strengthens the reliability of echocardiographic evaluation
of the right heart by including various echocardiographic
criteria in our setting. By ethical considerations it was not
possible to repeat right heart catheterization closed to
CPET in this severely diseased patient population.
Another limitation is the number of patients included in
this study. Therefore, wewere unable to usemulti-regression
statistical models to further focus on exercise-limiting
factors. Further studies have to be done to investigate the
reliability and prognostic importance of CPET in patients with
ILD. The population sample with PHT tended to be older and
moremale distribution compared to those without. However,
this difference did not reach statistical significance. We
assume that this mismatch in demographic characteristics
cannot explain the reported differences in peakVO2 or
ventilatory inefficiency.
In conclusion, PHT has a significant impact on exercise
capacity and dyspnoea in patients with ILD. The further
impairment of exercise capacity in patients with inter-
ceding PHT is attributable to a significantly impaired
ventilatory inefficiency. Analyzing gas exchange during
CPET offers potential explanations for exercise limitation in
patients with or without PHT and ILD. In addition, CPET in
ILD is a safe and easy to handle procedure which offers the
opportunity to characterize and quantify dyspnoea and
Impact of pulmonary hypertension on gas exchange 323exercise impairment. Further research has to be done to
investigate these methods and their potential prognostic
and therapeutic implications.Competing interests
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